TetraLogic Pharmaceuticals
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
33.3%
4 terminated/withdrawn out of 12 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Role: collaborator
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Role: collaborator
Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
Role: lead
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Role: lead
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Role: lead
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Role: lead
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Role: lead
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Role: lead
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Role: lead
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Role: lead
SHP-141C in Plaque Type Psoriasis
Role: lead
All 12 trials loaded